| Name | Title | Contact Details |
|---|
Southside Medical Center is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fitness classes, lap pool, personal training, weight-loss programs, Pilates, weight training and more. Free mini-membership. All ages and fitness levels welcome.
ProgenyHealth is a leading provider of care management solutions for premature and medically complex newborns. Our program promotes appropriate utilization, improves access, educates family members and reduces costs. Progeny`s foundation is built on evidence-based best practices, timely communication, and ongoing collaboration with clients and providers. This proactive approach has resulted in our expansion into 50 states and significant and reproducible cost savings for our clients.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.